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ABSTRACT (Maximum 200 Words)
The unique ability of dendritic cells to potently stimulate lymphocytes in an antigen-specific fashion has made them prime candidates for cancer immunotherapy. A number of tumor-derived products have been suggested to promote tumor establishment and progression by interfering with DC functions. One of the best characterized of these factors is Transforming growth factor-beta (TGF-Z), a multifunctional cytokine that exerts potent suppressive effects on cells of the immune system. TGF-8 specifically interferes with DC maturation, chemotaxis, antigen recognition and T cell activation. These findings strongly suggest that a strategy that protects DCs from the harmful effects of TGF-t should enhance the effectiveness of DC-based vaccines. In this study we show that TGF-B suppression of DC vaccines can be mitigated by inhibiting TGF-t gene expression in tumor cells and by neutralization of secreted TGF-t with specific antibody. We demonstrate that a novel small molecule TGF-3 type 1 receptor kinase inhibitor abrogates tumor-derived TGF-5-mediated signaling and epithelial-mesenchymal transition characteristic of a more invasive phenotype. The inhibitor enhanced the effectiveness of DC vaccines in controlling the growth of established 4Tl tumors. Taken together, our studies demonstrate the usefulness of eliminating immunosuppressive tumor-derived products in order to improve the effectiveness of dendritic cell-based anti-cancer vaccines. 
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Introduction
The unique ability of dendritic cells to potently stimulate naYve lymphocytes in an antigen-specific fashion has made them prime candidates for cancer immunotherapy. A number of tumor-derived products have been suggested to promote tumor establishment and progression by interfering with numerous DC functions required for the induction of a potent antitumor response. One of the best characterized of these tumor-derived factors is transforming growth factor-beta (TGF-13), a multifunctional cytokine that exerts potent suppressive effects on cells of the immune system. TGF-13 specifically interferes with DC maturation, chemotaxis, antigen recognition and T cell activation. By so doing, TGF-13 is capable of inhibiting the generation of effective DC-mediated anti-tumor immunity. As a corollary, strategies that protect or render DC resistant to the deleterious effects of TGF-P would be expected to improve the effectiveness of DC-based immunotherapy of cancer. The goal of this study is to protect DCs from the direct actions of tumor-derived TGF-13 in order to improve their effectiveness as cancer vaccines. The hypothesis to be tested is that interference with TGF-13 signal transduction in DCs will abrogate tumor-derived TGF-pmediated immunosuppression leading to more effective DC vaccines. The specific aims of this study are to: 1) determine the effect of tumor-derived TGF-13 on antigen presentation and in vivo migration of DCs. 2) evaluate the impact of tumor-derived TGF-13 on DC vaccines. 3) protect DCs from TGF-13-mediated immunosuppression by blocking TGF-1 signal transduction.
SPECIFIC AIM #1 Determine the effect of tumor-derived TGF-0 on DC antigen presentation and the migration a) Effect of tumor-derived TGF-fJ on DC antigen presentation
Antigen presentation by DC is suppressed by TGF-p
The presentation of antigen by DCs to T cells is dependent on the expression of MHC I, MHC II, and co-stimulatory molecules. Previous studies have shown that TGF-13 reduces expression of co-stimulatory molecules on DCs, therefore we evaluated its effects on the ability of DCs to stimulate T cells. Treatment of immature DCs with TGF-3 significantly reduced their ability to stimulate the proliferation of allogeneic T cells ( Figure  1A) . Immature DCs were also evaluated for their ability to present OVA peptide to, and stimulate the subsequent proliferation of naive OVA-specific CD4÷ T cells, which express a T cell receptor specific for the OVA MHC class II peptide. Treatment of immature DCs with TGF-13 for 6 days significantly impaired their ability to stimulate OVA-specific T cells ( Figure 1B 
TGF-j3 reduces the ability of DCs to stimulate tumor-sensitized T lymphocytes
Observing that TGF-p inhibits the antigen uptake and presentation capacities of DCs, we evaluated its effect on the stimulation of tumor-sensitized T lymphocytes. Mature DCs were more effective at stimulating the proliferation of tumor-sensitized T lymphocytes than immature DCs. TGF-p3-treatment significantly reduced the immunostimulatory ability of mature DCs (Figure 2A ). In contrast, TGF-p did not alter the immunostimulatory ability of immature DCs, which was already lower than that of mature DCs (Figure 2A ). The ability of immature and mature DCs to stimulate IFN-y production by tumor-sensitized lymphocytes was also significantly inhibited following TGF-13 exposure by 60% and 22% respectively ( Figure 2B ). Together these results demonstrate that TGF-13 exposure reduces the ability of DCs to stimulate anti-tumor immune responses. Figure 2 . Stimulation of tumor-sensitized T lymphocytes by TGF-P treated DCs. Dendritic cells were pulsed with tumor cell lysate for 48 hours in the presence or absence of 10ng/ml of TGF-y (immature DC), then cultured in TNF-y in the presence or absence of TGF-P for 48 hours (mature DC 
b) Effect of tumor-derived TGF-fi on DC migration
In vitro TGF-P treatment reduces DC migration to draining lymph nodes in vivo.
Following antigen internalization at the tumor site, it is advantageous for the dendritic cell to migrate to draining lymph nodes (DLNs) where tumor-specific T lymphocytes can be stimulated. The ability of dendritic cells to migrate from the periphery to secondary lymphoid organs following TGF-13 exposure was evaluated. Dendritic cells were labeled with PKH-67, a green fluorescent dye and injected subcutaneously (s.c.) into the hind flank of mice. Forty-eight hours following the injection, draining inguinal lymph nodes were removed. Migrated dendritic cells were enumerated by scanning laser cytometric analysis of cytospin preparations of the lymph node cell suspensions. The ability of mature dendritic cells to migrate to draining lymph nodes (DLNs) was significantly (p<0.05) inhibited following exposure to TGF-13 (Table 1) . In vivo exposure to tumor-derived TGF-P inhibits DC migration to tumor draining lymph nodes.
Observing that in vitro exposure to TGF-13 reduced the ability of DCs to migrate to DLNs we postulated that tumor-derived TGF-13 within the tumor microenvironment may have a similar effect, thus preventing DC migration from the tumor site to DLNs. To reduce the amount of tumor-derived TGF-13 within the tumor microenvironment, we utilized the 4T1-asT tumor cell line, which produces 90% less TGF-13 as compared to the 4T1-N (vector control) cell line. PKH-67 labeled DCs were injected intratumorally (i.t.) into established 4T1-N or 4T1-asT primary tumors. Forty-eight hours later, the tumor DLNs were removed, and the number of PKH-67÷, CDI 1c' double-positive DCs were determined by flow cytometry. DCs injected into 4T1-asT tumors exhibited an enhanced ability to migrate to tumor DLNs as compared to DCs injected into 4T1-N tumors ( Figure 3 ). These results suggest that tumor-derived TGF-13 reduces the ability of DCs to migrate to tumor draining lymph nodes thereby interfering with their capacity to stimulate tumor-specific T lymphocytes. TGF-P impairs the chemotactic migration of DCs. The migration of DCs from an inflammatory site such as a tumor to DLNs is regulated in part by the responsiveness of DCs to the chemokines (RANTES, MIP-la, MCP-1) produced within the tumor microenvironment and within DLNs (SLC, MIP-313). We evaluated whether the impairment of DC migration is a result of TGF-13 altering their responsiveness to various chemokines. Treatment of DCs with TGF-13 in vitro did not substantially alter their expression of chemokine receptor mRNA ( Figure 4A ). However, TGF-13 treatment reduced DC chemotaxis toward SLC and MIP-3p3 ( Figure 4B ), which may be the underlying mechanism for poor migration to DLNs. Figure 4 . Chemokine receptor expression and in vitro chemotaxis. DCs were matured with TNF-a in the absence or presence of TGF-P for 48 hours. (A) mRNA was isolated from DCs and chemokine receptor expression was analyzed by RT-PCR. Data are expressed as ratios compared with actin as determined by densitometry. (B) DC were added to the upper chamber of a transwell migration chamber and evaluated for chemotactic migration. Cells migrating to the bottom chamber were recovered and analyzed by flow cytometry for CD 11c expression. The results are mean±SEM of three independent experiments. Asterisk (*) refers to statistical significance between groups (p<0.05).
Phenotype of intra-tumorally injected DCs Because it has been shown that in vitro exposure to TGF-1 reduces the expression of co-stimulatory molecules on DCs, we postulated that TGF-P present in the tumor microenvironment might have the same effect on intra-tumorally injected DCs. In order to address this possibility, PKH-67-1abeled DCs were injected into established 4T1-Neo or 4T1-asT primary tumors. Forty-eight hours later, the tumors were removed and the numbers of cells positive for PKH-67 and either CD11c, I-Ad, CD40, CD80, or CD86 were determined. Only a small fraction (-10%) of the PKH-67÷ cells injected into the tumor were recovered. This may be the result of DC migration to other tissues, an inefficient recovery process, or DC demise in the tumor microenvironment. We did not observe any substantial differences in the numbers of CD11c÷, I-Ad÷, CD40÷, CD80÷ or CD86÷ cells recovered from 4T1-Neo or 4T1-asT tumors ( Figure 5A ). Analysis of tumor draining lymph nodes revealed that increased numbers of DCs migrated from 4T1-asT tumors as compared to 4T1-Neo tumors. As a result, an increased number of cells positive for both PKH-67 and either CD11c, I-Ad, CD40, CD80, or CD86 were present in DLNs from 4T1-asT tumor bearing mice as compared to those bearing 4T1-Neo tumors ( Figure 5B Effectiveness of in vivo antibody neutralization of TGF-p in improving DC immunizations The impairment of critical DC functions including antigen uptake, antigen presentation, tumor-specific T lymphocyte stimulation, and in vivo migration by TGF-13 suggested that inhibition of TGF-13 production in tumor-bearing animals might improve the efficacy of DC vaccines. To test this possibility, TGF-p production was suppressed by transfer of an antisense TGF-13 transgene into 4T1 cells (4Tl-asT). Expression of the transgene resulted in >90% inhibition of TGF-13 production (0.083 _t 0.003 ng/ml in 4T1-asT compared with 1.244 +_ 0.188 ng/ml in mock transduced cells (4T1-Neo). Treatment of 4T1-asT tumors with 2G7 mAb alone or DCs plus 2G7 mAb significantly inhibited tumor growth as compared with 4T1-asT tumors treated with DCs alone (Figure 6 ). Furthermore, complete tumor regression occurred in 40% (2/5) of 4T1 -asT-tumor bearing mice that were treated with DCs plus 2G7 mAb. Similarly, mock transduced (4T1-Neo) tumors responded significantly better (p<0.05) to treatment with DCs plus 2G7 mAb as compared to treatment with DCs alone; however tumor growth inhibition in this group was inferior to that observed in animals bearing 4T1-asT tumors ( Figure 6 ). Mice that exhibited complete tumor regression were re-challenged with parental 4T1 tumor cells to determine if they had developed long-term anti-tumor immunity. These mice failed to develop tumors (0/2); however all control naive mice challenged with tumor cells developed tumors (3/3). These data suggest that neutralization of TGF-13 in mice bearing TGF-P secreting tumors enhances the effectiveness of DC vaccines in treating established tumors. AdSmad7 mediates expression of Smad7 protein in DCs Our results show that tumor-derived TGF-13 significantly impairs the ability of DCs to treat established 4T1 tumors. To protect DC from the immunosuppressive effects of TGF-13 we constructed an adenoviral vector that contains the Smad7 gene linked to the FLAG fusion protein (AdSmad7). Smad7 inhibits the TGF-13 signaling pathway by preventing the binding of the TGF-13 receptor to Smad2. We successfully infected DC and demonstrated expression of the recombinant Smad7 protein by Western blot analysis. (Figure 7 ). DCs infected with the AdSmad7 express substantially higher levels of Smad7 protein as compared to those infected with AdLacZ (control vector). 
Treatment of established 4T1 tumors with AdSmad7 DCs
Having demonstrated the reduced responsiveness of DC infected with AdSmad7 to TGF-I3, we hypothesized that these DCs will be more effective stimulators of the anti-tumor immune response when injected into a TGF-p3-containing tumor microenvironment. Mice bearing established mock transfected (4T1-N) or anti-sense TGF-p-expressing (4T1-asT) tumors received i.t. injections of AdSmad7 DCs or AdLacZ DCs alone, or in combination with the TGF-P neutralizing antibody, 2G7. Unfortunately we did not observe a significant difference in tumor growth rates between the control and treatment groups ( Figure 9 ). However, treatment of the 4T1-asT tumor-bearing mice with Smad7-overexpressing DC enhanced production of IFN-y by their tumor draining lymph node cells, indicating an enhanced immunostimulatory capacity (Table 2 ). Table 2 . IFN-y production by tumor draining lymph nodes (TDLN) cells following vaccination with Smad7-overexpressing DC. TDLNs were removed from 4T1-asT tumor bearing mice (5 mice per group) following treatment as indicated above. One million TLDN cells were cultured for 48 hours in each well of a 24 well plate pre-coated with anti-CD3 antibody. Supernatants were removed and the amount of IFN-y present was determined by ELISA. Data represent mean±SEM of triplicate samples.
b) Abrogation of TGF-p mediated immunosuppression of DC using a small molecule TGF-fi inhibitor
Since DC transduced with Smad7 were ineffective at treating 4T1 tumors, we pursued an alternative strategy that could potentially be more effective in rendering DC resistant to TGF-13 signaling. This approach involved the use of a recently described TGF-1 receptor type I (TGFp-RI) small molecule kinase inhibitor, HTS466284 (1) . Unlike Smad7, HTS466284, interferes with TGF-13 signal transduction at the earliest step of the pathway by binding to the ATP pocket of TGF-13R1 and preventing its phosphorylation and activation.
HTS466284 is not toxic towards 4T1 cells in vitro
The potential toxicity of HTS466284 towards the highly metastatic 4T1 murine mammary carcinoma cell line was evaluated in vitro prior further studies to establish feasibility of use. 4T1 cells were treated with 1, 5, and 10 [M of HTS466284. Forty-eight hours after treatment the cells were harvested and counted for viability. HTS466284 treatment had no significant effect on cell viability up to 10 [M ( Figure 10 ). represents the mean±SEM of three independent experiments.
Inhibitor Concentration
HTS466284 blocks recombinant human TGF-01 signaling in vitro
The ability of HTS466284 to block recombinant human TGF-131(rhTGF-13) signaling was evaluated using the TGF-j3 inducible reporter PAI-luciferase. MvlLu cells that were transfected with p3TPLux as described previously were treated with HTS466284 for 30 minutes followed by the addition of rhTGF-131 (2ng/ml) for 18 hours. Extracts were then prepared and assayed for luciferase activity using the LucLite Plus kit (Perkin-Elmer, Boston, MA). Light emission was detected with a Packard Lumicount. HTS466284 inhibited rhTGF-131-induced expression of a transfected PAI-luciferase reporter in a dose dependent manner ( Figure 11 
HTS466284 blocks 4T1 tumor-derived TGF-P signaling in vitro
Observing that HTS466284 could block rhTGF-j31 mediated signaling, we next wanted to determine if the drug could block the effects of 4T1 tumor-derived TGF-13. Supernatants were collected from 24 hour 4T1 cultures and concentrated 15X using Centricon-10 concentrators (Amicon,lnc, Beverley, Mass.). The supernatants were treated with 1.2M HCI for one hour to activate any TGF-P3 present and TGF-P1 levels were quantified by ELISA (R&D Systems). MvlLu cells that were transfected with p3TPLux as described previously were treated with HTS466284 for 30 minutes followed by the addition of equivalent amounts of acid activated 4T1 derived TGF-13 for eighteen hours. Extracts were then prepared and assayed for luciferase activity using the LucLite Luciferase Assay kit (Perkin-Elmer, Boston, MA). Light emission was detected with a Packard Lumicount. HTS466284 inhibited tumor-derived, TGF-13-induced expression of a transfected PAIluciferase reporter in a dose dependent manner ( Figure 12 ). Figure 12 . Effect of HTS466284 on the expression of the TGF-P inducible gene reporter PAI-luciferase in response to 4T1 derived TGF-P. MvlLu transfected with the p3TPLux reporter were treated with 1, 5, and 10 [M of HTS466284 for 30 minutes followed by 18 hour treatment with ing/ml of 4T1 derived TGF-j31. Cell extracts were prepared using the LucLite Luciferase Assay kit (Perkin-Elmer, Boston, MA) and light emission was detected with a Packard Lumicount top-count luminometer. Data represents mean±SEM of triplicate samples.
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HTS466284 blocks rhTGF-A1 -mediated morphological changes in 4T1 cells in vitro
We have previously observed that TGF-1 treatment induces morphological changes in 4T1 cells indicative of epithelial to mesenchymal transition (EMT). These changes have been shown to be characteristic of highly malignant breast cancer cells. Therefore we evaluated the ability of HTS466284 to block TGF-1 mediated EMT. 4T1 cells were treated with 1, 5, or 101AM of HTS466284 for thirty minutes prior to the addition of 2ng/ml of rhTGF-I3 for 48 hours. Following treatment, the cells were observed for morphological changes. The 4T1 mammary tumor cell line normally adheres to plastic and grows in 13 rounded clumps ( Figure 13A ), but upon incubation with 2ng/ml rhTGF-P the cells became elongated, less clumped and assumed a fibroblast-like appearance ( Figure 13B ). HTS466284 treatment was able to block TGF-13 mediated EMT in 4T1 cells at all concentrations tested and these cells retained their normal clumped morphology ( Figure  13C-D) . TGF-p mediated EMT in the 4T1 cells could be restored if the HTS466284 treated 4T1 cells were washed with phosphate buffered saline (PBS) prior to the addition of rhTGF-13 ( Figure 14A-C Effect of combination DC + HTS466284 therapy on established 4T1 tumors in vivo.
C4
After we established that HTS466284 inhibits TGF-p signaling in vitro we evaluated the ability of HTS466284 to inhibit tumor progression in the TGF-I3-producing 4T1 murine mammary tumor model. For this purpose, HTS466284 was injected i.p. into BALB/c mice bearing pre-established 4T1 tumors. However, HTS466284 monotherapy did not significantly affect the growth of established 4T1 tumors in vivo (data not shown). Therefore, we evaluated if HTS466284 would able to improve the effectiveness of DC vaccines in a TGF-13-producing tumor microenvironment by treating mice bearing established 4T1 tumors with TNF-c matured, 4T1 lysate-pulsed DCs alone or in combination with HTS466284. The data (Figure 16 ) show that HTS466284 treatment in combination with DC vaccination significantly inhibited the growth of established 4T1 tumor to the same degree as mice treated with interleukin-12 (IL-12) plus DC. Furthermore, the increased anti-tumor activity in the DC + HTS466284 and DC + IL-12 groups was associated with increased IFN-y secretion by splenocytes compared to the control groups (Fig. 17) . Taken together, these data indicate that neutralization of tumor derived TGF-I3 by HTS466284 enhanced the effectiveness of DC-based immunotherapy in treating established 4T1 tumors. pooled and disaggregated. Splenocytes and lymph node cells were purified on a Ficol density gradient (Atlanta Biological, Lawrenceville, GA) and lx106 splenocytes were plated in 24-well plates for 48 hr. The supernatant was then collected and assayed for IFN-y by ELISA (Pierce, Rockford, IL) according to the manufacturer's protocol. Graph represents mean ± SD of three separate samples.
Key research accomplishments
1.
Determination of the effects of TGF-13 on the antigen presentation capacity, ability to stimulated T cell responses and the migratory capacity of DCs in vitro.
2. Determination of the effects of tumor-derived TGF-P on the ability of DC to migrate and DC phenotype in vivo.
3. Evaluation of the effect of neutralization of tumor-derived TGF-P in vivo on the effectiveness of DC vaccines.
4. Mitigation of TGF-13 signaling in DCs by inf6ction with AdSmad7.
5. Evaluation of the ability of AdSmad7-DCs to treat established 4T1 tumors and stimulate an immune response.
6. Demonstration of ability of the novel TGF-pR1 small-molecule kinase inhibitor to abrogate TGF-p signaling and prevent EMT in tumor cells. 
Conclusions
It is apparent from our research that tumor-derived TGF-P impairs the ability of Tumors. 4TI murine mammary tumor cells were kindly provided by Dr. antigen-pulsed DCs are effective in inducing CTL responses and Fred Miller (Michigan Cancer Foundation, Detroit, MI) and maintained as providing protection against subsequent tumor challenge (2-5). In described previously (21) . contrast, DC vaccines have been less effective in abrogating estab-TGF-13-neutralizing Antibody (2G7). The 2G7 mouse IgGI mAb was lished tumors in mice (2-5) and human cancer patients (6) . The generated after immunization of BALB/c mice with recombinant human TGFinsensitivity of established tumors to DC therapy is likely because of 03. 2G7 neutralized the growth inhibitory activity of TGF-P3,, TGF-13 2 , and factors present within the tumor microenvironment that are inimical to TGF-0 3 on MvlLu epithelial cells (22) . the optimal induction of an antitumor immune response (7). ExamiGeneration of DCs and TGF-13 Treatment. Bone marrow cells were nation of circulating and tumor-infiltrating DCs in tumor-bearing harvested from flushed marrow cavities of femurs and tibiae under aseptic sand in cancer patients has revealed that DCs are functionally conditions and cultured with 100 units/ml granulocyte macrophage colonyanimals stimulating factor and 100 units/ml interleukin 4 (Peprotech, Rocky Hill, NJ) impaired in their ability to induce T-cell responses (8) (9) (10) (11) . These at 106 cells/ml in complete media (RPMI 1640 containing 10% heat-inactideficits have been associated with down-regulation of MHC and vated FBS, 0.1 mm nonessential amino acids, I pXm sodium pyruvate, 2 mm L-glutamine, 100 /.g/ml streptomycin, 100 units/ml penicillin, 0.5 Ag/ml Received 5/28/02; accepted 2/18/03. fungizone, and 5 X 10-5 M 2-mercaptoethanol). Cytokines were replenished The costs of publication of this article were defrayed in part by the payment of page on day 4. On day 6 of culture, DCs were collected and cultured at 106 cells/ml charges. This article must therefore be hereby marked advertisement in accordance with with granulocyte macrophage colony-stimulating factor and interleukin 4 with 18 U.S.C. Section 1734 solely to indicate this fact.
' Supported by NIH Grants I ROI CA941 1-01 and DAMD 170010128 and DAMD or without the addition of 10 ng/ml of recombinant human TGF-P3 1 were stained with PE-conjugated anti-CD1 lc (BD PharMingen, San Diego, 4 The abbreviations used are: DC, dendritic cell; DLN, draining lymph node; mAb, CA), FITC-conjugated anti-I-Ad (BD PharMingen), PE-conjugated anti-B7.1 monoclonal antibody; FBS, fetal bovine serum; TGF-3, transforming growth factor P; (CD80), FITC-conjugated anti-B7.2 (CD86), or PE-conjugated anti-CD40. T TNF-a, tumor necrosis factor a; FACS, fluorescence-activated cell sorter; PE, r-phycoerythrin; OVA, ovalbumin; SLC, secondary lymphoid chemokine; MIP-313, macrophage cells were stained with PE-conjugated anti-CD3, FITC-conjugated anti-B220, inflammatory protein 3P.
PE-conjugated anti-CD8, or FITC-conjugated anti-CD4. Cells were analyzed 1860 TGF-13 NEUTRALIZING ANTIBODY AND DCs using a FACStarplus flow cytometer (Becton Dickinson Immunocytometry equivalents/DC for 24 h in the presence or absence of 10 ng/ml TGF-/3 1 . DCs Systems, San Jose, CA).
were then matured with 20 ng/ml TNF-a in the presence or absence of 10 Induction of Allogeneic Mixed Lymphocyte Reactions. Spleen cells ng/ml TGF-3I. Splenic T lymphocytes were purified from mice bearing 14 day from B6 mice were harvested and enriched for CD3-positive cells using a 4TI tumors as indicated above. Ten thousand DCs were incubated with T-cell enrichment column (R&D Systems were centrifuged (Shandon, Pittsburgh, PA) onto glass slides at 700 rpm for 4 says were performed using modifications of previously described procedures min. The slides were fixed with 4% paraformaldehyde and stained with a (23). Endocytosis was measured by incubating 2 X 10' DC with 400 lgg of propidium iodide/RNase solution (Phoenix Flow Systems, San Diego, CA). FITC-conjugated dextran beads, 40,000 MW (Molecular Probes, Eugene, OR) Slides were analyzed using a laser scanning cytometer (CompuCyte, Camfor 30 min at 4°C or 37°C. Phagocytosis was measured by incubating DCs with bridge, MA). Detection and contouring of cells was keyed by propidium iodide FITC-conjugated Escherichia coli (Molecular Probes) at a ratio of 100 E. coli signal, whereas DCs were identified by their green fluorescence signal; 35,000 particles to I DC for 60 min at 4°C or 37'C. After incubation, cells were propidium iodide events were analyzed from each treatment group/experiment. washed extensively with PBS containing 0.5% bovine albumin and 0.1%
The identity of each DC detected during scanning was confirmed visually by sodium azide and analyzed by flow cytometry.
direct microscopic observation using the instrument's relocation function.
Stimulation of Tumor-sensitized T Lymphocytes. Bone marrow-derived
In Vitro Chemotaxis Assay. Bone marrow-derived DCs were matured DCs were pulsed with 4TI tumor cell lysate at a ratio of 3 tumor cell with TNF-o in the presence or absence of TGF-13 1 for 48 h as indicated above. An in vitro chemotaxis assay was performed as described previously (24) . SLC 466 305 top chamber in serum-free media at a final volume of 100 g.l. After the plates Experiment 4 5500 5200 were incubated at 37'C in 5% CO 2 for 4 h, the cells in the bottom chamber DCs were cultured in the presence of 200 U/ml TNF-a with or without the addition of were recovered, the migrating cells were counted, and an aliquot was stained t0 ng/ml of TGF-03 for 48 hours. DCs were then labeled with PKH-67 membrane dye and with anti-CD II c mAbs to be analyzed by FACS. Controls included wells with injected s.c. into two naive BALB/c mice per group. Forty-eight hours following injection chemokine in both the top and bottom chambers. The number of migrated cells inguinal lymph nodes were harvested from mice and disaggregated. Lymph node cells was determined by subtracting the number of migrated cells in control wells were fixed and stained with Propidium Lodide/RNAse I solution and analyzed by laser scanning cytometry. Data are from four independent experiments. from the number of migrated cells in experimental wells.
*refers to statistical significance between groups (p < 0.05).
Treatment of Established Tumors. Six-week-old BALB/c mice were orthotopically injected with 104 4T I-N or 4Tl-asT tumor cells into the mam-40000-mary gland. DCs were pulsed with 4TI tumor cell lysate at a ratio of 3 tumor 
SLC
MIP-3P
Statistical Analysis. For all analyses, student t tests were performed using Prism software (GraphPad, San Diego, CA). Ps of <0.05 were considered to Fig. 3 . Effect of TGF-03 on in vitro chemotaxis. DCs were added to the upper chamber indicate significant differences between data sets. of a transwell migration chamber and evaluated for chemotactic migration. Cells migrating to the bottom chamber were recovered and analyzed by flow cytometry for CDI Ic expression. The results are mean ± SE of three independent experiments. * refers to RESULTS statistical significance between groups (P < 0.05).
Antigen Uptake and Presentation by DCs. Before evaluating the effect of TGF-13 in vivo, we evaluated its effects on several DC inhibited the endoocytic and phagocytic capacities of DCs by 58% functions in vitro. Treatment of DCs with TGF-P3 caused a significant and 87%, respectively (Fig. IC) , a pattern that was observed in all (P < 0.05) decrease in the levels of B7.1 and CD40 (Fig. IA) , as well three experiments conducted. To evaluate the effect of TGF-P3 expoas in the percentage of cells expressing CD40 (Fig. 1B) . Next, we sure on antigen presentation, mixed lymphocyte reactions were perevaluated the ability of DCs to endocytose dextran particles and formed. Stimulation of allogeneic T lymphocytes (Fig. ID) and presphagocytose E. coli particles after TGF-3 treatment. TGF-f3 exposure entation of OVA peptide (Fig. 1E) by DCs was significantly (P < 0.05) suppressed after TGF-P3 exposure. These results demonstrate that TGF-f3 inhibits the uptake and presentation of antigens by DCs.
A
Immature Mature Induction of Tumor-sensitized T Lymphocytes. Observing that 50000o 50000-TGF-p3 inhibits the antigen uptake and presentation capacities of DCs, 40000-4 0000J'--'I we evaluated its effect on the stimulation of tumor-sensitized T C 30000.-300 00 -, lymphocytes by tumor cell lysate-pulsed immature and mature DCs.
S20
0TGF-)3-treated mature DCs were significantly less effective 20000.
20000.
(P = 0.0002) than untreated mature DCs at stimulating the proliferooo -A10000. ation of tumor-sensitized T lymphocytes (Fig. 2A) . The ability of 0 . (Table 1) . This was a significant (P < 0.05) DCs were incubated with 2 X 10' splenic T cells isolated from mice bearing 4TI tumors for 5 days, and [ The finding that the antitumor effect expression was observed between untreated and TGF-f3-treated DCs was most evident when antisense TGF-p3-expressing tumors were (data not shown). TGF-/3 treatment caused reduced migration of DC treated with DCs plus anti-TGF-P3 mAb directly implicates tumortoward both SLC and MIP-33, however, only migration toward derived TGF-f3 in tumor progression. In our study, TGF-P3 within the MIP-313 was significantly decreased (P < 0.05; Fig. 3) .
tumor milieu could be promoting tumor growth by interfering with the Treatment of Established Tumors with DCs and Neutralizing antigen-presenting and effector functions of DCs at the tumor site, as TGF-13 Antibody. The impairment of critical DC functions, includwell as preventing the emigration of injected DCs to DLNs to activate ing antigen uptake and antigen presentation, tumor-specific T lymnai've tumor-specific T lymphocytes. The forner possibility is supphocyte stimulation, and in vivo migration by TGF-P3, suggested that ported by the recent findings by Kirk et al. (29) who suggested that inhibition of TGF-P3 production in tumor-bearing animals may immigration of i.t. injected DCs to DLNs is not required for the inducprove the efficacy of DC vaccines. To test this possibility, TGF-f3 tion of an antitumor response. Using SLC gene-modified DCs, they production was suppressed by transfer of an antisense TGF-P3 transdemonstrated comparable tumor growth inhibition in normal mice and gene into 4TI cells (4Tt-asT) as described previously (21). Expreslymphotoxin a-'-mice lacking peripheral lymph nodes (29) . The sion of the transgene resulted in >90% inhibition of TGF-P3 produclatter possibility is supported by the decreased chemotactic response tion (0.083 ± 0.003 ng/ml in 4Tl-asT compared with 1.244 ± 0.188 of TGF-03-treated DCs to MIP-3p3 and SLC observed in our study. ng/ml in mock-transduced cells (4TI-N) . Treatment of 4T1-asT tu-These chemokines produced in the lymph nodes recruit DCs via their mors with 2G7 mAb alone or DCs plus 2G7 mAb significantly interaction with the chemokine receptor, CCR7 (20, 30) . A possible inhibited (P < 0.05) tumor growth compared with 4T1-asT tumors explanation is that CCR7 gene expression is inhibited in DC by treated with DCs alone (Fig. 4) . Furthermore, complete tumor regres-TGF-13 treatment as has been reported by others (19, 20) . sion occurred in 40% (two of five) of 4T I-asT-tumor-bearing mice As with previously published studies (29, 31, 32) , only a minute that were treated with DCs plus 2G7 mAb (Fig. 4) . Similarly, mockfraction (<1%) of s.c. injected DCs in our study migrated to DLNs. transduced (4T1-N) tumors responded significantly better (P < 0.05)
It is yet to be determined if these lymph node-infiltrating DCs repreto treatment with DCs plus 2G7 mAb as compared with treatment sent a unique subpopulation capable of singularly stimulating the with DCs alone; however, tumor growth inhibition in this group was antitumor response or require the participation of endogenous DCs to inferior to that observed in animals bearing 4T1-asT tumors. (Fig. 4) . achieve this goal. In the setting of DC vaccination to prevent or treat Tumor growth was not affected by treatment with isotype control inaccessible micrometastases, it is desirable that adoptively trans-(IgG) antibody (data not shown). To determine whether the mice that ferred DCs are able to migrate to secondary lymphoid organs to exhibited complete tumor regression had developed long-term immustimulate naive T lymphocytes. Thus this LN-infiltrating, ex vivo nity, they were rechallenged with parental 4T1 tumor cells. These manipulated DC population needs to be more actively studied. mice failed to develop tumors (zero of two); however, all control In summary, this study demonstrates the potential usefulness of a naive mice challenged with tumor cells developed tumors (three of combined therapeutic approach to eliminate immunosuppressive three). These data suggest that neutralization of TGF-/3 in mice tumor-derived factors to improve the effectiveness of DC-based bearing TGF-p3-secreting tumors enhances the effectiveness of DC vaccines. vaccines in treating established tumors.
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anti-TGF-13 mAb significantly improved the antitumor activity of 2. Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. transfer (13, 21, 26) or abrogation of TGF-f3 using neutralizing 3. Coveney, E., Wheatley, G. H., III, and Lyerly, H. K. Active immunization using antibody (27, 28) Contrary to these findings of defective TGF-P signaling during tumor progression, several investigators have also reported increased production of TGF-P and retention of TGF-13 signaling pathways in malignant cancer cells [16, 7] . In the former case, tumor-derived TGF-P3 may promote tumor growth by suppressing several compartments of the immune system (summarized in Table 1 , also reviewed in 181), while in the latter case it can lead to increased invasiveness and metastasis of tumor cells [61. Table 1 Effects of TGF-O on cells of the immune system
Cell type Effects
T lymphocytes inhibits IL-2 dependent proliferation [56, 57] induces apoptosis [57.58] inhibits IFN-y secretion [57] CD4+ inhibits Th2 development [59] inhibits Thl development [60] induces IL-10 production via GATA-3/Smad3 interaction [611 inhibits secondary immune responses [62] induces proliferation of antigen specific Th2 cells [62] inhibits activation and cytokine secretion by antigen specific memory Thl cells [62] CD8+ inhibits CD8 expression in cultured PBL [63] inhibits cytotoxic activity and IFN-y production [64] induces suppressive CD8+ T cells [65] B lymphocytes inhibits antibody production [66] induces IgA synthesis [67] inhibits proliferation [68, 69] induces apoptosis [70, 71 ] inhibits expression of lgM, IgD, IgA, ic, and A. chains, and CD23 (FcSRII), transferrin receptor, and MHC class II expression [72] Monocytes/Macrophages induces expression of IL-I receptor antagonist protein [73] inhibits expression of MHC class II [74] inhibits expression of Fc Receptor [75] inhibits nitric oxide production [76] induces IL-10 production [77, 78] inhibits TNF-cx production [78] Dendritic Cells inhibits chemokine receptor expression and chemotactic migration [79] inhibits maturation [80] inhibits expression of DC-SIGN (CD209) [81] NK cells inhibits proliferation [82] inhibits IFN-y, TNF-ca, and GM-CSF production [82] This review will focus on the immunosuppressive role of tumor-derived TGF-j3 in mammary cancer progression in preclinical animal models and discuss strategies for counteracting the effects of TGF-P3 in order to enhance the antitumor immune response. To better understand the molecular basis of these therapeutic approaches, a brief review of the structure and signaling pathways of TGF-j3 is provided at the outset.
2. TGF-P3 structure and activation TGF-P belongs to the TGF-3 superfamily that is composed of numerous members including the TGF-P, activin/inhibins, and bone morphogenic protein (BMP) subfamilies. Several TGF-P3 isoforms have been identified including TGF-0 1 , which is the most extensively characterized. TGF-3 1 is secreted as a biologically inactive 290 kDa protein complex consisting of the TGF-t3I homodimer (25 kDa), and the latency associated protein (LAP) (75 kDa), which is associated with the latent TGF-3 1 3. Mechanisms of TGF-J0 signaling TGF-P3 mediates its biological activity by binding to TGF-3 receptor II (TI3RII) (Fig. I) . Upon binding to the ligand, TO3RII recruits TGF-fl receptor I (TO3RI) to form a heteromeric complex [20] . Additionally, the TGF-03 Type III receptor (betaglycan) and endoglin can bind TGF-P and facilitate its binding to TP3RII [21] [22] [23] . Both TP3RI and TIRII are serine-threonine kinases, composed of an extracellular ligand binding domain, a transmembrane domain, and a cytoplasmic serine-kinase domain. Downstream signaling is mediated by a series of structurally related proteins, termed Smads, originally identified by their similarity to the Drosophilia nmelanogaster Mothers against decapentaplegic (Mad) and the Caenorhabditis elegans sma gene products [24] [25] [26] . The binding of TGF-43 to the TGF-f3 receptor complex results in the GS sequence of T3RI being phosphorylated by the constitutively activated kinase domain of T3RII [20, 27, 28] . Smad2 is recruited to the membrane and presented to the TGF-13 receptor complex by the Smad anchor for receptor activation (SARA). Phosphorylation of TORI activates its downstream kinase domain, which in turn phosphorylates Smad2. Smad2 is next released from the TGF-13 receptor complex, binds to Smad4, and is translocated to the nucleus [29, 30] . The Smad2-Smad4 complex is able to regulate gene expression by directly binding to promoter regions of genes containing the Smad-binding element consensus sequence GTCTAGAC or by interaction with various DNA-binding transcription factors including FAST-I and FAST-2 [31] . 4. Effects of TGF-P1 on the immune system in breast cancer
Preclinical animal model studies
Although numerous studies have documented secretion of TGF-P3 by breast cancer cells [3,32. reviewed in 33] only a handful of studies have sought to demonstrate a connection between the immunosuppressive properties of tumor-derived TGF-P3 and mammary tumor progression. In one of the earliest studies to address this issue, Arteaga et al. [34] demonstrated that inoculation of the human MDA-231 breast cancer cell line into nude athymic mice decreased natural killer (NK) cell activity in splenocytes isolated from these mice. They also showed that intraperitoneal injection of the TGF-03 neutralizing antibody 2G7, restored NK function as well as suppressed intra-abdominal tumor and lung metastases. In contrast, ] also showed that tumor cell-conditioned medium inhibited the development of alloreactive CTL in vitro and that this effect could be blocked by adding neutralizing TGF-13 antibody or interleukin-2 (IL-2) to the cultures. Furthermore, they showed that transfer of the IL-2 gene into EMT6 cells caused tumor rejection. These results led them to propose that TGF-P contributed to the tumorigenic potential of EMT6 cells and that IL-2 can negate this activity. Since TGF-3 downregulates IL-2 receptor (IL-2R) expression by T cells making them less responsive to IL-2-induced proliferation and activation [38.1, a likely mechanism for the overriding effect of IL-2 is the reinduction of IL-2R expression via an autocrine pathway [39] . Follow-up studies by us [140,411 using this cell line provided the first direct evidence for the immunosuppressive role of tumor-derived TGF-j3 in mammary cancer progression. We showed that transfer and expression of a full length antisense TGF-P1 cDNA in EMT6 cells significantly suppressed tumor growth [40] and that this effect could be enhanced by interferon-y (IFN-y) gene transfer [41] . In vivo depletion of T lymphocyte subsets revealed that CD8+ T-cells were required for manifestation of the antitumor response [41 ] .
In another study by our group [42] using a poorly immunogenic, highly aggressive and metastatic mouse mammary tumor cell line (4T1), we demonstrated that ectopic expression of the antisense TGF-f3 transgene in these cells significantly inhibited the growth of primary tumors and the formation of lung, liver, and bone metastases. Histologic analyses revealed a predominantly lymphocytic infiltration of antisense TGF-J3-expressing tumors compared to the primarily neutrophilic infiltrate observed in mock-transduced tumors. In vivo T cell depletion studies implicated CD4+ and CD8+ T cells as the primary immune effectors of the antitumor response. Furthermore, in a residual disease setting in which primary tumors were excised and animals were treated for residual metastatic disease, we showed that vaccination of mice with tumor cells modified to co-express antisense TGF-P3 and IFN-y genes resulted in statistically significant prolongation of life [42] . IFN-y may act in an autocrine manner to mitigate TGF-P3 signaling in tumor cells, by stimulating expression of the inhibitory Smad, Smad7, and promoting formation of Smad7-Smurf2 (Smad ubiquitination regulatory factor-2) complex formation that results in TP3R degradation [43, 44] .
In more recent studies (unpublished data) we have shown that TGF-P3 also interferes with the inductive phase of the antitumor immune response by interfering with dendritic cell (DC) functions. Exposure to TGF-P3 inhibited the ability of DCs to present chicken egg ovalbumin (OVA) antigen, stimulate tumor-sensitized T lymphocytes, and migrate to draining lymph 
nodes [451.
In vivo studies also demonstrated that co-injection of 2G7 and tumor lysatepulsed DCs into pre-established 4T1 tumors resulted in significant tumor growth inhibition with tumor regression occurring in a few animals compared to tumors injected with only 2G7 or DCs. (Fig. 2A) . Furthermore, combination of 2G7 antibody treatment with inhibition of TGF-3 production by tumor cells via antisense TGF-f3 transfer (4Tl-asT) resulted in an improved antitumor effect (Fig. 213 ). Taken together, these studies demonstrate that tumorderived TGF-P3 contributes to mammary tumor progression by suppressing cellular immune responses.
Human studies
Unlike animal studies, little is known about the potential immunosuppressive role of TGF-P in human breast cancer. The available data are only correlative in nature. Elevated plasma levels of TGF-13 in breast cancer patients have been reported by several investigators [46, 47] . Other studies have also demonstrated that TGF-P3 immunoreactivity in tumor tissues positively correlates with lymph node involvement and disease progression [48---5 1 ]. Recently, Iwamoto et al. [52] demonstrated an inverse correlation between intratumoral TGF-P3 expression and content of mature (CD83 +) tumor-infiltrating dendritic cells (TIDC). The number of CD83 + tumor-infiltrating DCs was associated with relapse-free and overall patient survival [48] suggesting that the state of maturation of TIDC may be of prognostic significance. However, no direct causal link between TGF-P3 and DC maturation was shown in the study. Contrary to the above findings, Marrogi et al. [53] reported a positive correlation of TGF-f3 mRNA expression in tumor tissue with survival of breast cancer patients but not with the clinical stage of their disease. Since a similar correlation was not observed with TGF-13 protein expression, the prognostic value of this finding remains to be confirmed.
The association of TGF-P3 immunoreactivity of tumor tissue in invasive breast cancer with decreased survival and increased mortality suggest an immunomodulatory role for TGF-P3 in breast cancer progression. However, direct evidence of TGF-[3-mediated immunosuppression in breast cancer patients is yet to be provided. Further clinical investigation of the role of TGF-P3 in the progression of human breast cancer is imperative.
Conclusions and future directions
It is clear from the knowledge gleaned from preclinical animal studies that TGF-3 facilitates tumor progression, in part by interfering with the activitie8 of several immune effectors. Consequently, treatment strategies that eliminate or neutralize tumor-derived TGF-P3 such as administration of TGF-j3 neutralizing antibodies [34] , competing soluble TGF-f3 receptors [54] , and antisense TGF-P gene transfer would be expected to improve patient responsiveness to immune-based therapies for established tumors or residual metastatic disease following tumor debulking. Given the other tumor promoting effects of TGF-f3 [reviewed in 55] , these approaches will also be expected to have significant impact on tumor invasiveness and metastatic potential. One concern about such therapies that target tumorsecreted TGF-3 is the potential to interfere with the normal physiologic role of TGF-P in maintaining homeostasis. Whether or not this will be a major concern awaits future clinical trials in humans.
